NOVO_B Fundamentals are solid (for now), but risk for pharmaceutical placed tariffs and US vs EU trade war in the short term. Be careful. US administration is a wild card.
NVO The company will the most likely announce a big buy back program this quarter on the earnings, making the start of the upside. So do not hesitate to buy this insane noise...